Výsledky vyhledávání - "Catherine Lunven"

Investigation of new biomarkers of kidney injury in renal transplant recipients undergoing graft biopsy

Autor: Thomas O. Joos, Xavier Benain, Laurent Becquemont, Arthur Michon, Antoine Durrbach, Jean-Charles Gautier, Catherine Lunven, Alexandre Jagerschmidt, Thierry Gury, Catherine Aubert, Oliver Poetz

Publikováno v: Clinical transplantationREFERENCES. 35(9)

AIM Urinary and blood kidney biomarkers (BM) remain insufficient for early kidney injury detection. We aimed to compare new kidney BM with histopathological data in kidney allograft recipients. METHODS Blood and urine samples were collected from cons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da2e8cfd7fbf4e13e8a32adb2abd07df
https://pubmed.ncbi.nlm.nih.gov/34196434

Zobrazit plný text záznamu

Plný text ve formátu HTML

Investigation of novel biomarkers of drug-induced kidney injury in renal transplant recipients undergoing graft biopsy

Autor: Arthur Michon, Antoine Durrbach, Jean-Charles Gautier, Xavier Benain, Catherine Lunven, Alexandre Jagerschmidt, Catherine Aubert, Oliver Poetz, Thomas Joos, Thierry Gury, Laurent Becquemont

Urinary and blood kidney biomarkers (BM) remain insufficient to detect early kidney injury. Our aim was to compare new kidney BM with histopathological data in kidney allograft recipients. Blood and urine samples of consecutive adult patients were co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d00f2593ec87db3a8339ccce4a1f134c
https://doi.org/10.21203/rs.2.13591/v1

Zobrazit plný text záznamu

Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

Autor: Neli Boyanova, Sandrine Turpault, Catherine Lunven, Astrid Delfolie, Francesca Baldinetti, Ger-Jan Sanderink, Yann-Joel Beyer, Aziz Filali-Ansary, Amy OʼBrien

Publikováno v: Therapeutic Drug Monitoring

Background: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc0dc1b22401401cb4f18b72c9f8b1f
https://pubmed.ncbi.nlm.nih.gov/27015245

Zobrazit plný text záznamu

SSR182289A, a selective and potent orally active thrombin inhibitor

Autor: Mostapha Matrougui, Paul J. Schaeffer, Zsolt Bocskei, Janine Lorrain, Jean-Marc Herbert, Christopher N. Berry, Jean-Claude Jetha, Stephen E. O'Connor, Lassalle Gilbert, Jean-Michel Altenburger, Jean-Pascal Herault, Catherine Lunven, Daniel Galtier

Publikováno v: Bioorganic & Medicinal Chemistry. 12:1713-1730

SSR182289A 1 is the result of a rational optimisation process leading to an orally active thrombin inhibitor. The struc- ture incorporates an original 2-(acetylamino)-(1,1 0 -biphenyl)-3-sulfonyl N-terminal motif, a central l-Arg surrogate carrying a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd0af41662f5d32014d52712bca347fd
https://doi.org/10.1016/j.bmc.2004.01.016

Zobrazit plný text záznamu

SSR182289A, a Novel, Orally Active Thrombin Inhibitor: In Vitro Profile and ex Vivo Anticoagulant Activity

Autor: Christopher N. Berry, Jean-Michel Altenburger, Christian Pfersdorff, Frédérique Guilbert, Stephen E. O'Connor, Catherine Lunven, Jean-Pascal Herault, Lassalle Gilbert, Alain Lalé, Jean-Marc Herbert, Catherine Lecoffre

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 303:1189-1198

SSR182289A competitively inhibits human thrombin (K(i) = 0.031 +/- 0.002 microM) and shows good selectivity with respect to other human proteases, e.g., trypsin (K(i) = 54 +/- 2 microM), factor Xa (K(i) = 167 +/- 9 microM), and factor VIIa, factor IX

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05f703bcdca057674001bd1bc0f6ea61
https://doi.org/10.1124/jpet.102.040667

Zobrazit plný text záznamu

Anticoagulant Activity and Pharmacokinetic Properties of a Sub-cutaneously Administered Mixed Micellar Formulation of Argatroban in Experimental Animals

Autor: Nigel O. Roome, Catherine Lunven, Catherine Lecoffre, Bénédicte Roger, Nathalie Vivan, Danielle Garrigou-Gadenne, Christopher N. Berry, Pierre Lainée, Alain Rouchouse, Stephen E. O'Connor, Frederic Andre

Publikováno v: Thrombosis and Haemostasis. 84:278-285

SummaryWe have studied the anticoagulant properties of a novel mixed micellar formulation containing 14 mg/ml argatroban administered by the sub-cutaneous (s. c.) route to rats, rabbits, dogs and primates. Blood samples were taken at various times po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::860f359921a6da832558fae9a9205075
https://doi.org/10.1055/s-0037-1614008

Zobrazit plný text záznamu

Inhibition by Argatroban, a Specific Thrombin Inhibitor, of Platelet Activation by Fibrin Clot-associated Thrombin

Autor: Catherine Lecoffre, Donogh P. O’Brien, Christiane Gauffeny, Catherine Lunven, Nigel O. Roome, Christopher N. Berry

Publikováno v: Thrombosis and Haemostasis. 75:154-169

SummaryClot-associated thrombin retains amidolytic activity, and is resistant to inhibition by heparin, but not to low molecular weight thrombin inhibitors. We show that clot-associated thrombin induces platelet aggregation, is resistant to heparin:a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f97cdec9a44b07adb3fa71e73009bd94
https://doi.org/10.1055/s-0038-1650236

Zobrazit plný text záznamu

Effects of the Synthetic Thrombin Inhibitor Argatroban on Fibrin- or Clot-Incorporated Thrombin: Comparison with Heparin and Recombinant Hirudin

Autor: Christine Girardot, Catherine Lunven, Catherine Lecoffre, Christopher N. Berry

Publikováno v: Thrombosis and Haemostasis. 72:381-386

SummaryThe inhibitory effects of argatroban on clot- or fibrin-bound human thrombin were studied using the thrombin-specific chromogenic substrate S2238 (200 μM). These effects were compared to those of recombinant hirudin (rHV2 Lys 47) and the hepa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada866a9d2e1783cafabf9cb6b46c907
https://doi.org/10.1055/s-0038-1648875

Zobrazit plný text záznamu

Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor

Autor: Jean-Marc Herbert, Christopher N. Berry, Paul J. Schaeffer, L. Millet, Irène Lechaire, Catherine Lunven, Janine Lorrain, C. Visconte, M. Sainte-Marie, S. E. O'Connor, S. Lochot, P. Ferrari

Publikováno v: The Journal of pharmacology and experimental therapeutics. 304(2)

N -[3-[[[(1 S )-4-(5-Amino-2-pyridinyl)-1-[[4-difluoromethylene)-1-piperidinyl]carbonyl]butyl]amino]sulfonyl][1,1′-biphenyl]-2-yl]acetamide hydrochloride (SSR182289A) is a novel, potent, and selective thrombin inhibitor. We have examined the antith

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a88f8865f70ff195cbb4893247d5838
https://pubmed.ncbi.nlm.nih.gov/12538808

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání